DNA crosslinking and damage induction

DNA crosslinking and damage induction refer not to a single molecular target but rather a type of chemical lesion inflicted upon the genetic material by various exogenous agents—including chemotherapeutic drugs—and endogenous metabolic byproducts. Crosslinks can occur within one strand (intrastrand) or between two strands (interstrand) of the double helix; both forms disrupt critical cellular processes like replication and transcription. Interstrand links are particularly cytotoxic because they prevent separation of the two strands required for these processes.[1][3][4] Many anticancer drugs function by inducing these lesions—alkylating agents covalently bind nucleophilic sites on nucleotide bases while platinum-based compounds form stable adducts that distort helical structure.[3] If not repaired efficiently through specialized pathways involving excision repair enzymes or homologous recombination machinery,[4] these lesions lead to cell death—a property exploited therapeutically against rapidly dividing tumor cells. However, "DNA crosslinking/damage induction" is not itself a discrete therapeutic target like an enzyme or receptor; it describes a mechanism-of-action class affecting many possible molecular sites across genomic DNA. Therefore this entry is best classified as an effect/process rather than a canonical druggable target.[1][2]

Other names

DNA crosslinkingDNA damage inductionDNA interstrand crosslinkingDNA intrastrand crosslinkingDNA-protein crosslinking

Drugs that induce or exploit DNA crosslinks act by covalently linking nucleotides within the same strand or between opposite strands of the double helix. This blocks essential processes like replication and transcription, leading to cell cycle arrest and apoptosis—especially in rapidly dividing cells such as cancer cells. Some drugs also form bulky adducts with proteins bound to DNA, further disrupting cellular metabolism.[1][2][3][4]